Glickman Urololgical and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Urology. 2011 Apr;77(4):980-4. doi: 10.1016/j.urology.2010.09.063. Epub 2011 Jan 22.
To analyze the acceptance rate and durability of surveillance among contemporary men with low-risk prostate cancer managed at a large, US academic institution.
Patients with low-risk parameters on initial and repeat biopsy were offered surveillance regardless of age. Regular clinical evaluation and repeat prostate biopsy were recommended every 1-2 years, and intervention was recommended based on adverse clinical and pathologic parameters on follow-up. Acceptance rate of active surveillance, freedom from intervention, and freedom from recommended intervention were measured.
Of 202 low-risk patients, 86 (43%) chose immediate treatment and 116 (57%) underwent repeat biopsy for consideration of surveillance. Intervention was recommended after initial repeat biopsy in 27 (23%) men because of higher-risk features, leaving a total of 89 men on surveillance. Over a median follow-up of 33 months, 16 men were ultimately treated and 8 were recommended to undergo treatment because of adverse clinical features on subsequent evaluations. Of the men on surveillance, the 3-year freedom from intervention and freedom from recommended intervention was 87% (95% CI, 78-93) and 93% (95% CI, 85-97), respectively.
Acceptance of surveillance (57%) in low-risk patients in this series is substantially higher than previous reports, and approximately one-third of these patients are ultimately managed by surveillance using stringent criteria. The risk of reclassification to a more aggressive cancer over short-term follow-up in appropriately selected patients is low.
分析一家大型美国学术机构中低危前列腺癌男性患者接受监测的接受率和耐久性。
对初始和重复活检时具有低危参数的患者无论年龄如何均提供监测。建议定期进行临床评估和重复前列腺活检,每 1-2 年一次,并根据随访时的不良临床和病理参数推荐干预。测量主动监测的接受率、无干预和无推荐干预的自由度。
在 202 名低危患者中,86 名(43%)选择立即治疗,116 名(57%)进行重复活检以考虑监测。由于高危特征,在初始重复活检后,27 名(23%)男性建议进行干预,共有 89 名男性接受监测。在中位数为 33 个月的随访中,最终有 16 名男性接受治疗,8 名男性因后续评估时的不良临床特征而建议接受治疗。在接受监测的男性中,3 年无干预和无推荐干预的自由度分别为 87%(95%CI,78-93)和 93%(95%CI,85-97)。
在本系列中,低危患者接受监测(57%)的接受率明显高于以往报告,并且大约三分之一的患者最终通过严格标准进行监测管理。在适当选择的患者中,短期随访中重新分类为更具侵袭性癌症的风险较低。